BIIB VS HLN Stock Comparison

Performance

BIIB
74/100

BIIB returned -15.64% in the last 12 months. Based on SPY's performance of -20.65%, its performance is above average giving it a score of 74 of 100.

HLN
100/100

HLN returned 20.18% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

BIIB
73/100

32 analysts offer 12-month price targets for BIIB. Together, they have an average target of 294.73, the most optimistic target put BIIB at 405 within 12-months and the most pessimistic has BIIB at 209.

HLN

"Analyst Price Targets" not found for HLN

Sentiment

BIIB
70/100

BIIB had a bullish sentiment score of 70.25% across Twitter and StockTwits over the last 12 months. It had an average of 66.53 posts, 492.48 comments, and 835.41 likes per day.

HLN

"Sentiment" not found for HLN

Technicals

BIIB
14/100

BIIB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

HLN
50/100

HLN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

BIIB
61/100

BIIB has missed earnings 2 times in the last 20 quarters.

HLN
100/100

HLN has missed earnings 1 times in the last 20 quarters.

Profit

BIIB
64/100

Out of the last 20 quarters, BIIB has had 19 profitable quarters and has increased their profits year over year on 6 of them.

HLN
72/100

Out of the last 9 quarters, HLN has had 9 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

BIIB
40/100

BIIB has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

HLN
57/100

HLN has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Biogen Inc. Common Stock Summary

Nasdaq / BIIB

Healthcare

Drug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / HLN

Healthcare

Drug Manufacturers - Specialty & Generic

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Power up your portfolio